Market Research Logo

Oxford BioMedica Plc (OXB) - Financial and Strategic SWOT Analysis Review

Oxford BioMedica Plc (OXB) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Oxford BioMedica plc (Oxford Biomedica) is a gene and cell therapy company that focuses on developing novel treatments for serious diseases. The company along with its subsidiaries has developed LentiVector, a sector leading lentiviral vector delivery platform. It has also built a platform of special cutting-edge technologies and capabilities, based on LentiVector. Based on LentiVector delivery platform Oxford BioMedica has developed a portfolio of gene and cell therapy product candidates in cancer, ophthalmology and central nervous system (CNS) therapy areas. The company also provides lentiviral vector bioprocessing and process development services to partners. Oxford BioMedica is headquartered Oxford, the UK.

Oxford BioMedica Plc Key Recent Developments

Jun 06,2018: Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition
Jun 04,2018: Oxford BioMedica Announces Directorate Change
Mar 28,2018: Gyros Protein Technologies installs two Gyrolab xPlore systems at Oxford BioMedica for gene and cell therapy applications
Mar 15,2018: Board Change: Oxford BioMedica Appoints Heather Preston as Non-Executive Director
Mar 15,2018: Oxford Biomedica: Preliminary Results for the Year Ended 31 December 2017

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Oxford BioMedica Plc - Key Facts
Oxford BioMedica Plc - Key Employees
Oxford BioMedica Plc - Key Employee Biographies
Oxford BioMedica Plc - Major Products and Services
Oxford BioMedica Plc - History
Oxford BioMedica Plc - Company Statement
Oxford BioMedica Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Oxford BioMedica Plc - Business Description
Oxford BioMedica Plc - Corporate Strategy
Oxford BioMedica Plc - SWOT Analysis
SWOT Analysis - Overview
Oxford BioMedica Plc - Strengths
Oxford BioMedica Plc - Weaknesses
Oxford BioMedica Plc - Opportunities
Oxford BioMedica Plc - Threats
Oxford BioMedica Plc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Oxford BioMedica Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jun 06, 2018: Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition
Mar 28, 2018: Gyros Protein Technologies installs two Gyrolab xPlore systems at Oxford BioMedica for gene and cell therapy applications
Mar 15, 2018: Board Change: Oxford BioMedica Appoints Heather Preston as Non-Executive Director
Mar 15, 2018: Oxford Biomedica: Preliminary Results for the Year Ended 31 December 2017
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day
Jan 23, 2018: Oxford BioMedica announces £3 million grant awarded by Innovate UK
Aug 29, 2017: Oxford BioMedica: Stuart Paynter starts as new Chief Financial Officer
Aug 17, 2017: Oxford Biomedica: Interim Results For The Six Months Ended 30 June 2017
Mar 27, 2017: Oxford BioMedica Announces Publication in the Journal Nature Communications on Study Results Supporting the Transgene Repression in vector Production (TRiP) system
Mar 16, 2017: Oxford Biomedica Announces Preliminary Results for the Year Ended 31 December 2016
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Oxford BioMedica Plc, Key Facts
Oxford BioMedica Plc, Key Employees
Oxford BioMedica Plc, Key Employee Biographies
Oxford BioMedica Plc, Major Products and Services
Oxford BioMedica Plc, History
Oxford BioMedica Plc, Other Locations
Oxford BioMedica Plc, Subsidiaries
Oxford BioMedica Plc, Key Competitors
Oxford BioMedica Plc, Ratios based on current share price
Oxford BioMedica Plc, Annual Ratios
Oxford BioMedica Plc, Annual Ratios (Cont...1)
Oxford BioMedica Plc, Interim Ratios
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Oxford BioMedica Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Oxford BioMedica Plc, Performance Chart (2013 - 2017)
Oxford BioMedica Plc, Ratio Charts
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report